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Abstract: Infant formula is often used as a treatment for neonatal hypoglycaemia in Australia;
however, there are concerns that this may jeopardise mother-baby bonding and breastfeeding.
Successful use of glucose gel as an alternative treatment for hypoglycaemia has been reported.
We wanted to investigate in a pilot study whether the use of glucose gel has the potential to quickly and
safely restore normoglycaemia in the infants of diabetic mothers in an Australian setting. Infants with
asymptomatic hypoglycaemia were treated with glucose gel (n = 36) and compared to a historical group
of infants which had been treated with infant formula (n = 24). Within 15 min of the first treatment,
the gel group had a mean blood glucose level (BGL) of 2.6 mmol/L, and 2.7 mmol/L 30 min after
the second treatment. This was lower than the BGL after the first treatment for the formula group,
which rose to a mean of 2.8 then to 3.2 mmol/L after the second treatment (p = 0.003). In successfully
treated infants, administration of the gel resulted in normoglycaemia within 30 min. The likelihood of
special care nursery admission was not significantly different between the groups, although we had
a small sample size, and our findings should be interpreted with caution. These pilot results provide
support for further investigations into the use of glucose gel as an alternative treatment to infant formula.
Keywords: Glucose gel; hypoglycaemia; infant formula; neonate; diabetes; breastfeeding
1. Introduction
Transient, asymptomatic low blood glucose concentrations occurs frequently in newborns, and
may play a role in the stimulation of postnatal glycogenolysis and gluconeogenesis [1], development
of appetite, and the adaption to fast/feed cycles [2]. However, asymptomatic hypoglycaemia may
also indicate underlying metabolic disorders that can cause serious injury [2]. Hypoglycaemia in at-risk
groups, such as babies of diabetic mothers, can result in motor and neurological dysfunction if not properly
treated [3–5]. Therefore, it is imperative that nurseries are vigilant, and provide prompt, safe treatment for
all infants until it is determined that they can maintain normal glucose concentrations through fast-feed
cycles [2].
Unfortunately, there is currently a lack of consensus regarding the best method of treatment for
neonatal hypoglycaemia [3,6–8]. Within Australia and New Zealand (NZ), there is wide variation in
the treatment of asymptomatic hypoglycaemia within and between nurseries. Recent reviews have
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indicated that there is a paucity of studies to provide the type of data needed to establish a definitive
approach [9,10]. Furthermore, it is difficult to compare results of previous studies due to the different
types of blood glucose level (BGL) measurements taken (interstitial/continuous/heel-prick blood
samples), the accuracy of the measuring device used, the timing of treatments [11], the subsequent
timing of the BGL measurement [11], and the influence of the risk factors of the participants.
As maternal breast milk supply can often take a few days to become established, there is a need
for a treatment other than breast milk to be available. In Australia and NZ, infants who develop
asymptomatic hypoglycaemia, indicated by a BGL between 2.0 and 2.5 mmol/L, are most commonly
treated with infant formula [8,12]. However, midwives are concerned that treatment with infant
formula may jeopardise mother-baby bonding and the successful establishment of breastfeeding [13].
Alternative treatments therefore need to be investigated.
A potential alternative treatment is the sublingual administration of a 40% glucose gel [8,14].
At about US$2 per patient [15], or AU$4 in Australia, there is evidence that glucose gel is more effective
in raising BGL than breastfeeding alone [16–21]. The sublingual area has a thin, permeable epithelial
structure, with blood vessels draining directly into the jugular vein and moving quickly into the systemic
circulation, bypassing the hepatic first-pass metabolic processes. This provides improved bioavailability
over oral dosing [22]. The advantage of using the sublingual surface over the buccal area is that it limits
the amount of glucose to be absorbed, due to the saturability of the glucose carriers [23]. A rapid but
steady increase in BGL should reduce the incidence of rebound hypoglycaemia.
There are increasing numbers of diabetic mothers, as gestational and Type 2 diabetes rates
continue to rise throughout the world [24]. Hypoglycaemia is common in infants born to diabetic
mothers, as they are generally exposed to elevated maternal blood glucose levels during pregnancy.
This can lead to increased neonatal insulin levels and rapid use of available energy stores after birth,
placing them at high risk of hypoglycaemia. Almost half of Australian and NZ nurseries reported that they
did not treat the babies of diabetic mothers in the first three hours after birth, other than to breastfeed [8].
Given there are also doubts on formula being used as a treatment for at-risk infants with asymptomatic
neonatal hypoglycaemia in Australia, carefully designed clinical investigations are required to provide
reliable evidence for the best clinical practice for the treatment of hypoglycaemia [8]. In an effort to
contribute towards an important piece of this multifaceted puzzle, we investigated the use of glucose
gel, in conjunction with breastfeeding, for asymptomatic hypoglycaemia in infants of diabetic mothers in
a West Australian maternity hospital.
We undertook a pilot study of glucose gel treatment with matched historical records in order to
determine the feasibility of this treatment for future, larger studies. Our aim was to compare infants
who were treated with glucose gel with retrospective data of infants who were treated with infant
formula, to determine if glucose gel was as effective in rapid establishment of normoglycaemia and
prevention of special care nursery admissions.
2. Materials and Methods
This pilot study was conducted between August 2011 and June 2012 at King Edward
Memorial Hospital, Subiaco, Australia, to test the ability of glucose gel to normalise BGL (≥2.6 mmol/L).
2.1. Subjects
Infants born to diabetic mothers from ≥36 weeks gestation with asymptomatic hypoglycaemia
were eligible for inclusion. Asymptomatic hypoglycaemia is seen in otherwise healthy infants with
a BGL of between 2.0–2.5 mmol/L prior to the second breastfeed [6]. Recruitment of infants took place at
the antenatal clinic, whereby pregnant women (>18 years old) with diabetes (gestational, Type 1 or Type 2)
were approached. An information letter explaining the study was provided, and a signed consent form
collected. Inclusion of infants was only possible if they were admitted to a ward with an onsite blood
gas analyser, resulting in a convenience sample of infants admitted to the postnatal ward. Infants were
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excluded if they were symptomatic, had a BGL below 2.0 mmol/L, had any other health issues, were not
being exclusively breastfed, or if they were offered formula at any point during the study.
Retrospective data from medical records (from 1 March 2011 to 31 July 2011) was used for the formula
group. The historical controls were breast fed infants, with formula subsequently used in the treatment of
hypoglycemia. The same inclusion/exclusion criteria were applied, except that these infants were
treated with formula. The same measurements were taken for BGL, using the VITROS® system
(Ortho Clinical Diagnostics, NJ, USA).
A good match of characteristics of participants was achieved between the gel and the formula
groups (Table 1), with no significant difference (p > 0.05) in infant gender, weight, gestational age or
maternal age. However, there was a significant difference (p = 0.03) in the type of maternal diabetes,
with the gel group having 25% less mothers with gestational, and 2.8 and 5.5 times more Type 1 and
Type 2 diabetes respectively, compared to the formula group.
Table 1. Characteristics of hypoglycaemic infants born to diabetic mothers from both the glucose gel
treatment group and the historical infant formula group.
Mean± Standard Deviation
Infant Formula (n = 24) Glucose Gel (n = 36) p Value
Gender (male) 12 (50%) 20 (55%) 0.68
Weight (g) 3330 ± 392 3496 ± 518 0.16
Range 2870–4440 2665–4160
Gestational age (weeks) 38 ± 0.72 38 ± 1.12 0.27
Range 37–40 36–40
Maternal age (years) 33 ± 6 38 ± 1 0.27
Range 22–45 21–45
Type of maternal diabetes
Gestational 22 (92%) 24 (67%) 0.03
Type 1 1 (4%) 4 (11%)
Type 2 1 (4%) 8 (22%)
2.2. Protocol
A flow chart of the methodology used is shown in Figure 1. Glucose concentrations were determined
using the glucose oxidase method with blood gas analyser (ABL 90 Flex, Radiometer, California, USA)
via whole blood capillary heel prick lancing [6]. For the gel group, BGL was determined at 15 min post
treatment 1, and at 30 min if a second dose of the glucose gel was administered. Treatment was considered
successful if the infant’s BGL reached ≥2.6 mmol/L. The formula group followed the Figure 1 protocol,
with the BGL processed in the on-site hospital laboratory. Due to the use of historical data as a control
group, it was not possible to tightly control protocol, and there were likely to be differences in the timing
of feeds and testing.
All infants treated with glucose gel were exclusively breastfed, and BGL was tested prior to the second
breastfeed (within four hours of birth), in order to diagnose hypoglycaemia. Continued breastfeeding was
encouraged throughout the treatment period. Initial treatment for the hypoglycaemic infant was a 40%
dextrose gel (Glutose 15, Paddock Laboratories, Minneapolis, MN, USA). A 2 mL sterile syringe measured
a dosage of 0.5 mL/kg of body weight [20]. The glucose gel was administered sublingually with
a gloved hand, after sterile gauze was used to first dry the area to enhance absorption. The midwives
were responsible for administering the glucose gel. They participated in two one-hour training sessions
where the correct technique in applying the glucose gel was demonstrated. However, it was realized
within the first few weeks that there was often not enough space to apply the dose sublingually, so any
remaining gel was massaged into the buccal membrane.
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using an independent t test. A Chi Squared test of contingencies, with a significance level of p < 0.05, 
was used to compare treatments with regard to special care nursery admission. 
3. Results 
3.1. BGL Response to Treatments 
Starting with the same mean baseline BGL of 2.3 ± 0.2 mmol/L, both treatment groups saw a rise 
of BGL following the first treatment (Figure 2). While the mean of the gel group reached the desired 
mark of 2.6 mmol/L for normalisation of BGL, the mean of the BGL in the infant formula group rose 
Figure 1. Protocol for selection and treatment of infants, of diabetic mothers, suffering hypoglycaemia
for trial of buccal application of glucose gel treatment. BGL: blood glucose levels, BW: body weight.
2.3. Approval
The study was approved by The Women’s and Newborn Health Service Ethics Committee
(1905/EW) and The Edith Cowan University Human Research Ethics Committee (6541).
2.4. Statistical An lysis
Statistical analysis was performed using Predictive Analytics Software for Windows, version 18.0 2009
(SPSS Inc., IBM, Chicago, IL, USA). The means of both treatment groups were compared using
an independent t test. A Chi Squared test of contingencies, with a significance level of p < 0.05, was used
to compare treatments with regard to special care nursery admission.
3. Results
3.1. BGL Response to Treatments
St rting with the same mean baseli e BGL of 2.3± 0.2 mmol/ , bot treatment groups saw a rise of
BGL following the first treatment (Figure 2). While the mean of the gel group reached the desired mark
of 2.6 mmol/L for normalisation of BGL, the mean of the BGL in the infant formula group rose above this
(p = 0.07). The mean BGL of the infant formula group continued to increase after the second treatment,
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reaching a mean of 3.2± 0.6 mmol/L, and creating a significant difference between the groups (p = 0.003).
The gel group had a smaller variance in the BGL after both treatments, compared to the formula group.
In the gel group, 64% of infants were administered a second treatment, while 96% of the infant formula
group were administered a second treatment (Figure 2).
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than genuinely demonstrating no difference between groups. Special care nursery admission is 
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Figure 2. Means of blood glucose response to either infant formula or glucose gel treatment in
hypoglycaemic infants born to diabetic mothers. Error bars represent standard error. Blood glucose
levels (BGL) were measured 15 min after the first treatment; where required, a second treatment was
administered, then the BGL was measured again after 30 min.
3.2. Time to Normoglycemia
In successfully treated infants in the glucose gel group, all had reached normoglycemia within 30 min.
3.3. Special Care Nursery Admiss on
Ninety-six percent of the for ula group—compared to 81% of infants treated with glucose
gel—avoided special care admission. This difference was not determined to be significant (χ2 = 0.2;
p = 0.08). A retrospective power calculation (percentage, two sample, one-tailed) found that our study had
52.2% power to detect whether the treatment group had a significantly higher rate of admission to special
care than the control group, at the 0.05 level [25].
3.4. Adverse Reactions
No infants had an adverse reaction to the glucose gel.
4. Discussion
The results of this pilot study contribute to the establishment of a new standard of care for neonatal
hypoglyca mia. Our findings sug est that the use of glucose gel is worth investigating as an effective
treatment for hypoglycaemia in Australia. If successful, this treatment has the potential to contribute
to a reduction in related lengths of hospital stays and costs [10,20,26,27]. Although our results
showed that special care nursery admission, in infants diagnosed with asymptomatic hypoglycaemia,
did not significantly differ with treatment of glucose gel or infant formula, based on the differences
detected and our final sample sizes, results may be due to being under-powered rather than genuinely
demonstrating no difference between groups. Special care nursery admission is generally detrimental
to bonding and establishment of breastfeeding, and is highly stressful for parents and neonates [10].
Mothers in continuous contact with their infants are found to produce more milk, breastfeed longer,
and are more likely to exclusively breastfeed [28].
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Glucose gel treatment resulted in a quick establishment of normoglycaemia (within 15 min) for
36% of infants. This supports findings of other researchers: Harris et al. measured at 20 min [29];
Harris et al. at 10 min (sugar powder) [20], while Ter et al. found an increase at 10 min, with a peak
at 40 min [21]. Our results showed that a higher percentage of infants in the formula group received
a second treatment. The measurement of BGL for the formula group in our study was conducted in
the hospital laboratory rather than being ward based, and there may have been some delays in receiving
results which lead to unnecessary second treatments. Although our results support formula as an effective
treatment for hypoglycemia, there remains little evidence on the time to peak BGL for formula treatments,
and no evidence-based guideline for the volume of formula required for treatment [16]. Our first gel
treatment resulted in a mean BGL of 2.6 mmol/L, with low variance in the group. This more gradual
change in BGL produced by glucose gel was also reported by others [30], and a normal range of BGL
achieved, without rebound or recurrent hypoglycaemia [20,23,27,29] and no hyperglycaemic reactions [27].
Importantly, there were no adverse effects from using gel, as reported in previous studies [9,20,31].
Our study showed that infant formula is also an effective treatment, resulting in the greatest
increase in BGL, also reported by Harris et al. [16]. The second treatment in the current study resulted in
an average BGL of 3.2 mmol/L, significantly higher than the gel results. However, a higher BGL is not
necessarily better, as higher post-treatment plasma glucose in infants with neonatal hypoglycaemia has
been associated with poor neurodevelopment at two years of age, suggesting a ‘U’-shaped relationship
between neonatal glucose concentrations and neurodevelopmental impairment [32]. Higher BGLs are
more likely to result in rebound hypoglycaemia [23].
The importance of breastfeeding infants—due to its immunological and nutritional value—
is scientifically supported by multiple organisations, including the World Health Organisation [33].
However, with many hospitals still promoting formula as a treatment for hypoglycaemia, there are
many concerns that this may contribute to lower breastfeeding duration [13,34]. Disruption of
the establishment and duration of breastfeeding can result in increased risk of infections and allergies,
and alterations in the neonatal microbiome [16]. The use of infant formula may decrease a mother’s
confidence in her own breast milk and breastfeeding ability, potentially reducing the chance of
successful breastfeeding, and also the duration of breastfeeding [34,35]. This is of particular importance
in our growing population of diabetic mothers, as mothers who continue breastfeeding decrease the risk
of their child experiencing metabolic disorders later in life [35,36]. A consistent result from studies on
the use of glucose gel is the improvement in exclusive breastfeeding rates [10,20,27,30,37].
The use of the glucose gel dose is less invasive than IV treatment and less disruptive to
breastfeeding than formula; however, sublingual application proved difficult in some infants where
the area for application was very small. As a result, some applications were sublingual with
the remainder massaged into the buccal membrane. This may result in some of the gel being swallowed.
Swallowing of the gel decreases the bioavailability of the glucose, due to reliance on gastrointestinal
and hepatic metabolism, as opposed to the direct passage to the systemic circulation if absorbed [38].
This could be overcome by more frequent sublingual applications of gel.
Administration of a small amount of sucrose for pain relief prior to BGL testing [39] was an exclusion
criteria for this study, however this may not have been necessary. A Cochrane review on this topic [40]
found that the only study to investigate effect of sucrose on BGL found no significant difference in
BGL between babies to whom sucrose had been administered, compared to those given a placebo
(sterile water) in a double blind, randomized controlled trial [41]. Future studies may decide to omit this
as an exclusion criterion.
The type of maternal diabetes differed between gel and formula groups in our study, with the formula
group having a higher proportion of gestational diabetes and lower proportions of Type 1 and Type 2
diabetes. In all types of diabetes, blood glucose control is key to minimizing adverse effects; therefore, it is
difficult to say whether the type of diabetes would make a difference to our findings. It is also possible
that some mothers with gestational diabetes may have already had undiagnosed Type 2 diabetes.
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The use of glucose gel with breastfeeding was associated with reduced requirement for repeat
gel treatment. Research indicates that breastfeeding may have a slower, more sustained effect on
BGL than infant formula or dextrose gel [16]. Glucose gel supplies a rapidly absorbed and digested
carbohydrate, and is therefore useful as a first line treatment, followed up by breast milk as a slower-acting
carbohydrate [16]. The use of glucose gel has been shown to increase breastfeeding rates upon
discharge from hospital, compared to other treatments; nonetheless, larger studies are required to
empirically test the long-term effects on breastfeeding. Our study provides support for a large-scale,
Australian randomized controlled trial to provide more definitive data on the treatment of hypoglycemic
infants. In terms of preventing hypoglycaemia for infants at risk (including preterm, small or large, as well
as having a mother with diabetes), a randomized, multicenter, placebo controlled trial is underway in
Australia and NZ [42]. This trial plans to investigate whether a preventative dose of gel can reduce
admission to special care along with improving breastfeeding and maternal satisfaction.
5. Conclusions
Our results support previous research in other countries, indicating that sublingual/buccal glucose
gel is a promising treatment in infants diagnosed with asymptomatic hypoglycaemia. The glucose gel
treatment provided rapid and controlled improvements in BGL. The formula group had a larger increase
in BGL with greater variance in response. There were no adverse reactions to glucose gel, and we did not
detect significant differences in special care nursery admissions between the two groups, although we
were underpowered for this outcome. Our results must be interpreted with caution, given our low
subject numbers. While some individual Australian hospitals have developed protocols utilizing glucose
gel treatment, many do not. Further research into glucose gel treatment is required to justify development
of uniform policies across the region.
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